Showing 8661-8670 of 10252 results for "".
- Revelle Aesthetics Rolls Out Avéli to Treat Cellulitehttps://practicaldermatology.com/news/revelle-aesthetics-rolls-out-aveli-to-treat-cellulite/2461189/
- CeraVe Shares Real Stories of Four Nurses with the Return of Heroes Behind the Maskshttps://practicaldermatology.com/news/cerave-shares-real-stories-of-four-nurses-with-the-return-heroes-behind-the-masks/2461186/In honor of National Nurses Week, CeraVe reinforces its commitment to the nursing community with the premiere of
- Laser Dermatologist Dr. Rox Anderson Inducted Into National Inventors Hall of Famehttps://practicaldermatology.com/news/laser-dermatologist-dr-rox-anderson-inducted-into-national-inventors-hall-of-fame/2461171/
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of der
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat
- New GEM-3 Phase 3 Results for B-VEC Presented at 2022 AAD Annual Meetinghttps://practicaldermatology.com/news/new-gem-3-phase-3-results-for-b-vec-presented-at-2022-aad-annual-meeting/2461136/Krystal Biotech, Inc
- Get to Know Allergan Aesthetics’ Allē Flashhttps://practicaldermatology.com/news/get-to-know-allergan-aesthetics-alle-flash/2461135/
- Update: Skin Reactions to COVID-19 and Its Vaccineshttps://practicaldermatology.com/news/update-skin-reactions-to-covid-19-and-its-vaccines/2461125/